{{'Search' | translate}}
 

Recombinant human TPO

重组人TPO

公司名称: PeproTech
产品编号: 300-18
Bio-protocol()
Company-protocol()
Other protocol()

Differentiation of Human Induced Pluripotent Stem Cells (hiPSCs) into Osteoclasts
Author:
Date:
2020-12-20
[Abstract]  

Defects in bone resorption by osteoclasts result in numerous rare genetic bone disorders as well as in some common diseases such as osteoporosis or osteopetrosis. The use of hiPSC-differentiated osteoclasts opens new avenues in this research field by providing an unlimited cell source and overcoming obstacles such as unavailability of human specimens and suitable animal models. Generation of hiPSCs is well established but efficient differentiation of hiPSCs into osteoclasts has been challenging. Published hiPSC-osteoclast differentiation protocols use a hiPSC-OP9 co-culture system or

...
[摘要]  [摘要]破骨细胞引起的骨吸收缺陷导致许多罕见的遗传性骨疾病以及某些常见的疾病,例如骨质疏松症或骨质疏松症。采用的hiPSC -分化破骨细胞通过提供无限的细胞来源和克服障碍,如人体标本和合适的动物模型的可用性打开了该领域的新途径。hiPSC的生成已被公认,但是将hiPSC高效分化为破骨细胞一直具有挑战性。发布的hiPSC -osteoclast分化协议使用的hiPSC-OP9共培养体系或hiPSC细胞来源的胚状 具有多种细胞因子的机体(EB)。我们的三阶段协议包含:1)中胚层EB分化,2)的扩张骨髓单核细胞和3)的成熟的hiPSC -osteoclasts。我们通过在Nunclon Sphera微孔板上培养Accutase分离的hiPSCs来产生大小均一的EB,并在4天的细胞因子混合物中促进EB中胚层分化。对于第2阶段,将EBs转移至明胶包被的平板中,并用hM -CSF和hIL-3培养,以扩增骨髓单核细胞群。通过与维生素d,补充hTGF β,HM -CSF和hRANKL ,在第2阶段结束时收集的细胞的diff erentiated成成熟破骨细胞(第3阶段)。与其他技术相比,我们的协议不需要共培养系统。诱导EBs分化为中胚层 均匀的方式; 使用较少的细胞因子进行分化;只需要很短的时间就可以使破骨细胞成熟,并产生足够数量的破骨细胞用于后续的分子分析。

图形摘要: ...

Generation of T cells from Human and Nonhuman Primate Pluripotent Stem Cells
Author:
Date:
2020-07-05
[Abstract]  Pluripotent stem cells (PSCs) have the potential to provide homogeneous cell populations of T cells that can be grown at a clinical scale and genetically engineered to meet specific clinical needs. OP9-DLL4, a stromal line ectopically expressing the Notch ligand Delta-like 4 (DLL4) is used to support differentiation of PSCs to T-lymphocytes. This article outlines several protocols related to generation of T cells from human and non-human primate (NHP) PSCs, including initial hematopoietic differentiation of PSC on OP9 feeders or defined conditions, followed by coculture of the OP9-DLL4 cells ... [摘要]  [摘要] 多能干细胞(PSCs)有潜力提供同质的T细胞群体,这些细胞可以在临床规模上生长,并通过基因工程来满足特定的临床需求。OP9-DLL4是一种异位表达Notch配体Delta-like 4(DLL4)的基质细胞系,用于支持psc向T淋巴细胞的分化。本文概述了从人类和非人类灵长类(NHP)PSC中产生T细胞的几种方法,包括在OP9喂食者或特定条件下对PSC进行初始造血分化,然后将OP9-DLL4细胞与PSC衍生的造血祖细胞(HPs)共培养,从而有效地分化成T淋巴细胞。此外,我们描述了一个从有条件表达ETS1的hPSCs中产生健壮T细胞的方案。所提出的协议提供了一个平台,用于疾病建模和评估其在大型动物模型免疫治疗中的应用。

[背景] T淋巴细胞(T细胞)在细胞介导的免疫反应中起着关键作用,参与肿瘤细胞的监测和杀伤。在过去的几十年里,已经开发了几种策略来重定向、培养和/或增强抗肿瘤的T淋巴细胞(Houot等人,2015年;June等人,2018年),并将其用于基于T细胞的过继免疫治疗。最近的临床试验表明,用嵌合抗原受体(CAR)-T细胞治疗复发性和难治性淋巴瘤患者的疗效显著(Riviere和Sadelain,2017)。

人类多能干细胞(hPSCs),包括胚胎(hESCs)和诱导(hiPSCs),为生产用于过继性细胞免疫疗法的T细胞提供了一种很有前景的资源,可与基因工程技术相结合,产生现成的CAR ...

iPS Cell Induction from Human Non-T, B cells from Peripheral Blood
Author:
Date:
2013-09-20
[Abstract]  The generation of iPS cells gives an opportunity to use patient-specific somatic cells which are a valuable source for disease modeling and drug discovery. To promote these studies, it is important to make iPS cells from easily accessible and less invasive tissues like blood. Here, we describe the basic method to generate human iPS cells from adult peripheral blood. After the isolation of mononuclear cells, a combination of cytokines stimulates the expansion of hematopoietic stem/progenitor population, which is the main target of this protocol. The cells are transduced with plasmid mixture ... [摘要]  iPS细胞的产生提供了使用患者特异性体细胞的机会,其是用于疾病建模和药物发现的有价值的来源。 为了促进这些研究,重要的是使iPS细胞从容易获得和侵入性较小的组织如血液。 在这里,我们描述从成人外周血生成人类iPS细胞的基本方法。 在分离单核细胞后,细胞因子的组合刺激造血干/祖细胞群的扩增,这是该方案的主要目标。 用编码重编程因子的质粒混合物转导细胞。 在大多数情况下,质粒在iPS克隆的建立期间丢失。

产品评论